Stockreport

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray) [Yahoo! Finance]

ARS Pharmaceuticals, Inc.  (SPRY) 
PDF challenge (NAC) conditions, and updated testing that detected no measurable nitrosamine levels, conducted per August 2023 FDA Guidance Submission of CRL response trigg [Read more]